As I hope you will see in this article, A Tale of Two Annexes. Learn From Europe? How An Emerging Biopharma Changed Its Supply Chain Methodology And What It Learned. Last week, I p.

The next step forward for RTT legislation is unclear. Maybe it is time to put politics aside and focus on patients. Acceptable Risk Reduces Clinical Development Time. The Challenge Of Scaling From 20 Sites To 200. Ensure A Smooth Start-Up In Gene Therapy Trials. The purpose of a comprehensive assessme.

Can Your Clinical Supply Chain Pass The Brexit Pressure Test? Clinical trial sponsors and clinical supply vendors must fully consider all attributes of their supply chains to ensure continuity of supply post-Brexit. This whitepaper outlines many questions that sponsors and vendors alike should ask. Avoiding Delays In Clinical Supply.

Critical Opportunity For Pharmaceutical And Process Understanding. How To Drive Down Laboratory Operating Costs With SaaS. Improve Data Integrity And Quality For Life Sciences Infographic. Improve data integrity and quality, ensure IP protection, increase efficiency, and collaboration and enable faster and better decision making. Streamlining Change Control In Toda.

We facilitate engagement across the drug development life cycle through our web portals, publications, events, and training - learn more about our products below. Is your single source for everything relate.

The Intriguing Origins Of A Gene Therapy Biopharma. Quality Adds Empathy To Outsourcing. ALSO IN THIS MONTHS ISSUE. Vertical Mergers Of Rx Supply Chain Spark Antitrust Concerns. Intricate Supply Chain Complicates Gene Therapy Manufacturing. With the General Data Prote.

Buying More Time For Stroke Victims. How To Structure Your Internal Audit Program. The One Tattoo You Will Never Regret. A Device For Providing Better Drug Outcomes.

And by the way, so do the global regulators of biopharma. Biopharma Outsourcing Will Overcome Tariff Troubles. 6 Challenges For BioPharma Packaging. 3 Questions To Guide You At Biopharma Conferences.

With patents for dozens of biologic drugs expected to expire within the next five years, the value of bringing biosimilar alternatives to the market has never been clearer for drug manufacturers.